LIVIVO - Search results -

Search results

Result 1 - 10 of total 66

Search options

Article ; Online: Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy by Narayan et al.

Judge, Sean J / Cho, May / Gholami, Sepideh

2022 Volume 29, Issue 12, Page(s) 7246–7247

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/surgery ; Fluorouracil/therapeutic use ; Genomics ; Hepatectomy ; Hepatic Artery/pathology ; Humans ; Infusions, Intra-Arterial ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Liver Neoplasms/surgery
Chemical Substances	Fluorouracil (U3P01618RT)
Language	English
Publishing date	2022-07-12
Publishing country	United States
Document type	Editorial
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-022-12198-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: A painful mass in the jaw.

Patel, Kanishka G / Huynh, Jasmine C / Liu, James / Aronowitz, Paul / Cho, May

Cleveland Clinic journal of medicine

2022 Volume 89, Issue 1, Page(s) 27–35

MeSH term(s)	Humans ; Pain
Language	English
Publishing date	2022-01-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	639116-3
ISSN	1939-2869 ; 0891-1150
ISSN (online)	1939-2869
ISSN	0891-1150
DOI	10.3949/ccjm.89a.20156
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function.

Huynh, Jasmine / Cho, May Thet / Kim, Edward Jae-Hoon / Ren, Min / Ramji, Zahra / Vogel, Arndt

Therapeutic advances in medical oncology

2022 Volume 14, Page(s) 17588359221116608

Abstract: Background: Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib : Methods: We retrospectively evaluated patients from REFLECT who deteriorated to CP-B : ...

Abstract	Background: Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib Methods: We retrospectively evaluated patients from REFLECT who deteriorated to CP-B Results: Patients with CP-B Conclusion: Results suggest that patients with uHCC whose liver function deteriorates to CP-B after initiation of therapy may continue to receive lenvatinib. Trial registration: ClinicalTrials.gov, NCT01761266, https://clinicaltrials.gov/ct2/show/NCT01761266.
Language	English
Publishing date	2022-08-24
Publishing country	England
Document type	Journal Article
ZDB-ID	2503443-1
ISSN	1758-8359 ; 1758-8340
ISSN (online)	1758-8359
ISSN	1758-8340
DOI	10.1177/17588359221116608
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting.

Gholami, Sepideh / Abidalhassan, Mustafa / Cho, May / Saeed, Anwaar / Rocha, Flavio G

Journal of gastrointestinal cancer

2022 Volume 54, Issue 2, Page(s) 672–676

Abstract: Purpose: To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022.: Methods: We reviewed the abstracts presented at ASCO GI 2022. The studies ... ...

Abstract	Purpose: To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022. Methods: We reviewed the abstracts presented at ASCO GI 2022. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on clinical practice. Results and conclusion: This year's hybrid ASCO-GI symposium (2022) introduced many promising new treatment strategies in GI oncology, with several changes in clinical practice for patients with advanced hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic colorectal cancer (CRC).
MeSH term(s)	Humans ; United States ; Carcinoma, Hepatocellular ; Liver Neoplasms/therapy ; Gastrointestinal Neoplasms/diagnosis ; Gastrointestinal Neoplasms/therapy ; Gastrointestinal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Medical Oncology/methods ; Bile Duct Neoplasms ; Bile Ducts, Intrahepatic/pathology
Language	English
Publishing date	2022-07-19
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	2452514-5
ISSN	1941-6636 ; 1559-0739 ; 1941-6628 ; 1537-3649
ISSN (online)	1941-6636 ; 1559-0739
ISSN	1941-6628 ; 1537-3649
DOI	10.1007/s12029-022-00849-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Medullary carcinoma of the duodenum treated with pembrolizumab: a case report.

Liu, Louisa / Kaur, Simmer / Dayyani, Farshid / Cho, May / Ran-Castillo, Dani / Chong, Esther / Khandelwal, Keerti / Demisse, Rahel

Journal of gastrointestinal oncology

2023 Volume 14, Issue 2, Page(s) 1149–1154

Abstract: Background: Medullary carcinoma (MC) is a recognized histologic subtype of colorectal cancer characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate. However, MC originating from the small intestine is exceedingly rare, ...

Abstract	Background: Medullary carcinoma (MC) is a recognized histologic subtype of colorectal cancer characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate. However, MC originating from the small intestine is exceedingly rare, with only nine cases described in the literature. Based on previous cases, surgical resection is currently the mainstay of treatment for those with localized disease. We report the first case of a patient who presented with unresectable microsatellite instability-high (MSI-H) MC of the duodenum and was instead treated with pembrolizumab. Case description: A 50-year-old man with history of adenocarcinoma of the proximal descending colon status post hemicolectomy and adjuvant treatment with chemotherapy and family history of Lynch syndrome presented with abdominal pain for two weeks. Computed tomography (CT) abdomen/pelvis revealed a 10.7 cm by 4.3 cm mass in the mid-portion of the duodenum abutting against the pancreatic head. Esophagogastroduodenoscopy (EGD) demonstrated circumferential, partially obstructing, intrinsic stenosis of the duodenum with ampullary involvement and likely invasion into the pancreatic head and common bile duct. Endoscopic biopsy of the primary tumor revealed poorly differentiated MC. Immunohistochemical staining showed loss of MLH1 and PMS2 expression. Staging with CT chest showed no evidence of disease. Positron emission tomography (PET) scan redemonstrated circumferential duodenal wall thickening and hypermetabolic activity with standardized uptake value (SUV) max of 26.4, as well as PET-avid epigastric, retroperitoneal, and periaortic lymphadenopathy suggestive of metastasis. He was started on pembrolizumab and found to have stable disease on repeat imaging along with significant improvement in symptoms and performance status. Conclusions: Due to the rarity of the tumor, there is no standardized approach to treatment. All patients in previously published cases underwent surgical resection. However, our patient was deemed a poor surgical candidate. Given his previous history of colon cancer and treatment with platinum-based therapy, he qualified for pembrolizumab as first line therapy for his MSI-H tumor. To our knowledge, this is the first report of MC of the duodenum as well as the first MC to be treated with pembrolizumab in the first line setting. In order to corroborate the use of immune checkpoint inhibitors as a treatment option for MC of the colon or small intestine, the aggregation of existing and future case data in this unique patient group is certainly warranted.
Language	English
Publishing date	2023-03-06
Publishing country	China
Document type	Case Reports
ZDB-ID	2594644-4
ISSN	2219-679X ; 2078-6891
ISSN (online)	2219-679X
ISSN	2078-6891
DOI	10.21037/jgo-22-755
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.

Dayyani, Farshid / Balangue, Jasmine / Valerin, Jennifer / Keating, Matthew J / Zell, Jason A / Taylor, Thomas H / Cho, May T

Clinical colorectal cancer

2023 Volume 23, Issue 1, Page(s) 67–72

Abstract: Introduction: This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC).: Patients and ... ...

Abstract	Introduction: This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC). Patients and methods: Single institution investigator-initiated phase 1 study using 3+3 design. Eligible mCRC patients had received prior standard regimens. Cabozantinib was given orally (p.o.) at 20 mg (dose level [DL] 0) or 40 mg (DL 1) daily on days 1-28, and FTD/TPI p.o. at 35 mg/m Results: Fifteen patients were enrolled. Median age 56 years (31-80), male (12/15), ECOG 0/1 = 9/6. Three patients were treated at DL 0 and another nine were treated at DL 1, none exhibiting a DLT. Most common any grade (G) treatment related adverse events (TRAE) were diarrhea (50%), nausea (42%), neutropenia (42%), fatigue (33%), and rash (25%). G3-4 TRAE were neutropenia (25%) and thrombocytopenia, hypokalemia, and weight loss (each 8%). No serious TRAE or G5 were reported. The RP2D was determined to be DL 1. Median PFS was 3.8 months (95% CI 1.9-6.8) and disease control rate was 86.7%. Conclusion: The combination of cabozantinib and FTD/TPI is feasible and tolerable at standard doses with the use of growth factors and showed encouraging clinical activity in refractory mCRC. Clinicaltrials: GOV: NCT04868773.
MeSH term(s)	Humans ; Male ; Middle Aged ; Uracil/adverse effects ; Trifluridine ; Frontotemporal Dementia/chemically induced ; Frontotemporal Dementia/drug therapy ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Drug Combinations ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Adenocarcinoma/drug therapy ; Adenocarcinoma/secondary ; Neutropenia/chemically induced ; Anilides ; Pyridines ; Pyrrolidines ; Thymine
Chemical Substances	tipiracil (NGO10K751P) ; cabozantinib (1C39JW444G) ; Uracil (56HH86ZVCT) ; Trifluridine (RMW9V5RW38) ; Drug Combinations ; Anilides ; Pyridines ; Pyrrolidines ; Thymine (QR26YLT7LT)
Language	English
Publishing date	2023-11-27
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2112638-0
ISSN	1938-0674 ; 1533-0028
ISSN (online)	1938-0674
ISSN	1533-0028
DOI	10.1016/j.clcc.2023.11.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5798: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 435: Show issues

Order via subito

Details ▾

Article: Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.

Lee, Patrick C / Hendifar, Andrew / Osipov, Arsen / Cho, May / Li, Daneng / Gong, Jun

Cancers

2021 Volume 13, Issue 7

Abstract: Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents ... ...

Abstract	Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fibroblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarcinoma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.
Language	English
Publishing date	2021-04-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13071706
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.

Huynh, Jasmine / Patel, Kanishka / Gong, Jun / Cho, May / Malla, Midhun / Parikh, Aparna / Klempner, Samuel

Current treatment options in oncology

2021 Volume 22, Issue 11, Page(s) 100

Abstract: Opinion statement: Data supporting the use of immunotherapy in the treatment of gastroesophageal cancer continues to evolve. The promising results from adjuvant immunotherapy and trials combining immunotherapy plus chemotherapy in the 1L setting have ... ...

Abstract	Opinion statement: Data supporting the use of immunotherapy in the treatment of gastroesophageal cancer continues to evolve. The promising results from adjuvant immunotherapy and trials combining immunotherapy plus chemotherapy in the 1L setting have led to broad US FDA approvals. Among the PD-L1 negative subgroups, the magnitude of benefit is diminished; effective therapy for this population remains an unmet need. A detailed biologic understanding of the PD-L1 negative (and low) population represents a barrier to developing effective combination therapies, although combination angiogenesis inhibitors and immunotherapy look encouraging. Early phase clinical trials, particularly with pembrolizumab plus lenvatinib (EPOC 1706), demonstrated a clear signal independent of PD-L1, and a confirmatory phase III trial of pembrolizumab plus lenvatinib is planned. Conceptually, it is important to think of immune checkpoint inhibitor therapy as targeted therapy, most active in clearly defined biomarker-selected populations. Pre-planned analyses have reliably shown a clear trend toward a greater magnitude of benefit in patients with higher PD-L1 expression, particularly CPS ≥ 5 and ≥ 10. Whether there is a linear relationship at higher cutoffs is not well known, though it likely represents smaller and smaller populations. Although beyond the scope of this clinically oriented review, recognition of the spatial and temporal heterogeneity in PD-L1 expression is important and repeat testing from progression samples across lines of therapy should be considered. Questions about additional predictive biomarkers, particularly plasma-derived, remain. Responses by tumor histology and location also differ, and special attention to these factors as well as MSI-H, HER2, and EBV subgroups in future trials is warranted. Questions regarding the incorporation of immunotherapy after progression on 1L immunotherapy plus chemotherapy combinations will arise as these combinations are used more frequently, and this represents a key area of future investigation. Overall, the role of immunotherapy continues to expand in GEA, and we welcome any additional tools for this difficult-to-treat group of cancers.
MeSH term(s)	Biomarkers, Tumor ; Clinical Decision-Making ; Clinical Trials as Topic ; Combined Modality Therapy/adverse effects ; Combined Modality Therapy/methods ; Disease Management ; Drug Resistance, Neoplasm ; Esophageal Neoplasms/diagnosis ; Esophageal Neoplasms/etiology ; Esophageal Neoplasms/therapy ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Molecular Targeted Therapy/methods ; Recurrence ; Retreatment ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/etiology ; Stomach Neoplasms/therapy ; Treatment Outcome
Chemical Substances	Biomarkers, Tumor ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2021-09-15
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2057351-0
ISSN	1534-6277 ; 1527-2729
ISSN (online)	1534-6277
ISSN	1527-2729
DOI	10.1007/s11864-021-00893-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5523: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: BRCA

Devico Marciano, Naomie / Kroening, Gianna / Dayyani, Farshid / Zell, Jason A / Lee, Fa-Chyi / Cho, May / Valerin, Jennifer Goldstein

Cancers

2022 Volume 14, Issue 10

Abstract: The discovery ... ...

Abstract	The discovery of
Language	English
Publishing date	2022-05-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14102453
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.

Dayyani, Farshid / Tam, Kit / Kim, Edward J / Ejadi, Samuel / Valerin, Jennifer / Taylor, Thomas H / Cho, May T

Medical oncology (Northwood, London, England)

2022 Volume 39, Issue 5, Page(s) 102

Abstract: TAS-102 is approved for treatment of refractory metastatic gastroesophageal carcinoma (mGEC). This study sought to determine whether the combination of TAS-102 with irinotecan (TASIRI) was safe and effective in previously treated mGEC. This was a single- ... ...

Abstract	TAS-102 is approved for treatment of refractory metastatic gastroesophageal carcinoma (mGEC). This study sought to determine whether the combination of TAS-102 with irinotecan (TASIRI) was safe and effective in previously treated mGEC. This was a single-arm phase 1b study for patients (pts) with mGEC previously treated with at least one line of fluoropyrimidine and platinum-containing regimen. TAS-102 was given at 25 mg/m
MeSH term(s)	Adenocarcinoma/drug therapy ; Antineoplastic Combined Chemotherapy Protocols ; Drug Combinations ; Esophageal Neoplasms/drug therapy ; Humans ; Irinotecan/therapeutic use ; Platinum/therapeutic use ; Pyrrolidines/therapeutic use ; Stomach Neoplasms/drug therapy ; Thymine/therapeutic use ; Trifluridine/therapeutic use
Chemical Substances	Drug Combinations ; Pyrrolidines ; trifluridine tipiracil drug combination ; Platinum (49DFR088MY) ; Irinotecan (7673326042) ; Thymine (QR26YLT7LT) ; Trifluridine (RMW9V5RW38)
Language	English
Publishing date	2022-05-23
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Multicenter Study
ZDB-ID	1201189-7
ISSN	1559-131X ; 0736-0118 ; 1357-0560
ISSN (online)	1559-131X
ISSN	0736-0118 ; 1357-0560
DOI	10.1007/s12032-022-01698-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1899: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito